Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 11 | 2015 | 25 | 1.520 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2015 | 193 | 1.090 |
Why?
|
| Ovarian Neoplasms | 7 | 2018 | 77 | 0.880 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2012 | 201 | 0.710 |
Why?
|
| Peritoneal Neoplasms | 4 | 2010 | 9 | 0.590 |
Why?
|
| Uterine Neoplasms | 5 | 2014 | 12 | 0.490 |
Why?
|
| Benzimidazoles | 1 | 2015 | 9 | 0.470 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2011 | 7 | 0.430 |
Why?
|
| Salvage Therapy | 2 | 2011 | 34 | 0.360 |
Why?
|
| Leiomyosarcoma | 2 | 2014 | 9 | 0.300 |
Why?
|
| Middle Aged | 22 | 2018 | 8556 | 0.260 |
Why?
|
| Adult | 19 | 2018 | 7517 | 0.260 |
Why?
|
| Female | 25 | 2018 | 14543 | 0.250 |
Why?
|
| Aged | 20 | 2018 | 8658 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 42 | 0.230 |
Why?
|
| Aged, 80 and over | 14 | 2015 | 4633 | 0.230 |
Why?
|
| Rectovaginal Fistula | 1 | 2004 | 1 | 0.230 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2004 | 11 | 0.220 |
Why?
|
| Radiation Injuries | 1 | 2004 | 24 | 0.220 |
Why?
|
| Surgical Flaps | 1 | 2004 | 48 | 0.220 |
Why?
|
| Neoplasm Staging | 6 | 2011 | 339 | 0.210 |
Why?
|
| Paclitaxel | 2 | 2015 | 49 | 0.210 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 15 | 0.200 |
Why?
|
| Humans | 25 | 2018 | 25900 | 0.180 |
Why?
|
| Carcinosarcoma | 2 | 2014 | 4 | 0.180 |
Why?
|
| Disease-Free Survival | 8 | 2015 | 149 | 0.170 |
Why?
|
| Brachytherapy | 4 | 2010 | 46 | 0.160 |
Why?
|
| Cisplatin | 4 | 2010 | 55 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 141 | 0.160 |
Why?
|
| Chimerism | 1 | 2018 | 5 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 5 | 0.150 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 5 | 0.150 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 139 | 0.140 |
Why?
|
| Administration, Oral | 2 | 2015 | 99 | 0.130 |
Why?
|
| Radiotherapy, Conformal | 2 | 2010 | 19 | 0.130 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 149 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 160 | 0.130 |
Why?
|
| Fibrillar Collagens | 1 | 2015 | 1 | 0.120 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2015 | 2 | 0.120 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 3 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 9 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2011 | 63 | 0.120 |
Why?
|
| Quinazolines | 1 | 2015 | 16 | 0.120 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2015 | 1 | 0.120 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2012 | 80 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 1 | 0.110 |
Why?
|
| Epothilones | 1 | 2014 | 2 | 0.110 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2014 | 1 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 3 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2014 | 17 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 381 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2014 | 37 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2004 | 33 | 0.100 |
Why?
|
| Survival Rate | 2 | 2011 | 294 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 14 | 0.100 |
Why?
|
| Carcinoma, Papillary | 1 | 2011 | 25 | 0.090 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2010 | 3 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2010 | 13 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 14 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 25 | 0.090 |
Why?
|
| Sesquiterpenes | 1 | 2010 | 4 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2011 | 45 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2014 | 3339 | 0.090 |
Why?
|
| Vagina | 2 | 2015 | 36 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 164 | 0.080 |
Why?
|
| Radiometry | 1 | 2010 | 25 | 0.080 |
Why?
|
| Genital Neoplasms, Female | 1 | 2010 | 14 | 0.080 |
Why?
|
| Mifepristone | 1 | 2009 | 1 | 0.080 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2009 | 2 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2009 | 4 | 0.080 |
Why?
|
| Laparotomy | 1 | 2009 | 18 | 0.080 |
Why?
|
| Pyrazines | 1 | 2009 | 9 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2010 | 161 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2009 | 146 | 0.070 |
Why?
|
| Vaginal Neoplasms | 2 | 2004 | 3 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 1708 | 0.070 |
Why?
|
| Pelvic Neoplasms | 2 | 2004 | 9 | 0.070 |
Why?
|
| Quality of Life | 1 | 2009 | 563 | 0.060 |
Why?
|
| Thigh | 1 | 2004 | 30 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 2004 | 15 | 0.060 |
Why?
|
| Vinblastine | 1 | 2004 | 5 | 0.050 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2003 | 1 | 0.050 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2003 | 4 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2002 | 32 | 0.050 |
Why?
|
| Mitomycin | 1 | 2002 | 10 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2012 | 21 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2010 | 286 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2011 | 69 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2010 | 98 | 0.030 |
Why?
|
| Mutation | 1 | 2018 | 319 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 28 | 0.030 |
Why?
|
| Connective Tissue | 1 | 2015 | 24 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 55 | 0.030 |
Why?
|
| Indazoles | 1 | 2014 | 3 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2015 | 639 | 0.030 |
Why?
|
| Hysterectomy | 2 | 2003 | 23 | 0.030 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2010 | 2 | 0.020 |
Why?
|
| Dioxoles | 1 | 2010 | 5 | 0.020 |
Why?
|
| Ovarian Diseases | 1 | 2010 | 1 | 0.020 |
Why?
|
| Taxoids | 1 | 2010 | 11 | 0.020 |
Why?
|
| Bortezomib | 1 | 2009 | 3 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 6 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 200 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 24 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 328 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2006 | 4 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 6 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 31 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2006 | 50 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2006 | 44 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 355 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 1083 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 12 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 1815 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 1929 | 0.010 |
Why?
|
| Cystadenocarcinoma | 1 | 2003 | 2 | 0.010 |
Why?
|
| Life Tables | 1 | 2003 | 5 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 2003 | 15 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2003 | 39 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2003 | 89 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 149 | 0.010 |
Why?
|
| Sarcoma | 1 | 2003 | 74 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2002 | 51 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 125 | 0.010 |
Why?
|
| Prognosis | 1 | 2003 | 695 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 611 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 540 | 0.010 |
Why?
|